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Summ a r y
Gigantism results when a growth hormone–secreting pituitary adenoma is present 
before epiphyseal fusion. In 1909, when Harvey Cushing examined the skeleton of 
an Irish patient who lived from 1761 to 1783,1-3 he noted an enlarged pituitary 
fossa. We extracted DNA from the patient’s teeth and identified a germline muta-
tion in the aryl hydrocarbon–interacting protein gene (AIP). Four contemporary 
Northern Irish families who presented with gigantism, acromegaly, or prolactino-
ma have the same mutation and haplotype associated with the mutated gene. Using 
coalescent theory, we infer that these persons share a common ancestor who lived 
about 57 to 66 generations earlier.
P ituitary adenomas are usually benign, slow-growing tumors that cause symptoms due to excess hormone release, local space-occupying effects, or both. Adenomas that secrete excess growth hormone cause acro-
megaly. Patients with acromegaly have numerous symptoms and signs, such as 
hyperhidrosis, prognathism, frontal skull bossing, thickened skin, diabetes melli-
tus, hypertension, sleep apnea, osteoarthritis, and headache, as well as enlargement 
of the hands, feet, heart, and other internal organs. Large adenomas expand the 
pituitary fossa and can lead to visual-field defects and interfere with the production 
of other pituitary hormones, such as gonadotropic hormones, thyroid-stimulating 
hormone, or adrenocorticotropin.4 Increased prolactin levels are often noted in such 
patients owing to cosecretion of growth hormone and prolactin (since somatotrophs 
and lactotrophs have a common developmental origin), pressure on the pituitary 
stalk, or both.
Untreated acromegaly leads to increased mortality as a result of cardiovascular, 
cerebrovascular, and pulmonary dysfunction and is associated with a 30% de-
crease in life expectancy.4 Acromegalic gigantism is most often caused by a pitu-
itary adenoma that secretes excess growth hormone, with the onset of the disorder 
before epiphyseal fusion.5 Although extreme stature characterized these patients 
in the past, a timely diagnosis and the combination of surgery, medical therapy, 
and radiation therapy can now usually control the output or the effect of growth 
hormone and avert a marked increase in height. It has recently been recognized 
that in acromegaly of childhood onset, patients occasionally have a family history 
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of acromegaly or prolactinoma; some of these 
families have a mutation in the gene encoding 
the aryl hydrocarbon–interacting protein (AIP), 
which predisposes them to pituitary adenoma for-
mation.6-13 In addition, some patients with child-
hood-onset pituitary adenoma and no apparent 
family history have been shown to have germline 
AIP mutations.14,15 In our cohort of 140 families 
with familial isolated pituitary adenoma,10,13 we 
identified four families from Northern Ireland 
with the same AIP mutation (c.910C→T, p.R304X) 
(Fig. 1A, 1B, and 1C), which is known to be a 
mutational hot spot.6,7,10,18 Functional cell-prolif-
eration and protein–protein binding assays have 
shown that this mutation results in a truncated, 
dysfunctional protein.10 In view of the geo-
graphic clustering of the c.910C→T mutation, 
we explored the possibility that an 18th-century 
giant from Northern Ireland (the index patient), 
whose skeleton is preserved, and the four North-
ern Irish families we identified inherited the 
same mutation from a common ancestor.
Patien t s
The index patient was born in Northern Ireland 
in 1761. As a child he grew rapidly, and in his late 
teens he was featured in street shows in Ireland. 
At the age of 19 years, he traveled to London to 
exhibit himself in similar settings. A contempo-
rary etching shows him in the company of twin 
brothers, also giants, who were born in a neigh-
boring village (12 km away) and who were said to 
be related to him3 (Fig. 1D). His general health 
slowly deteriorated, and he died at 22 years of age. 
Subsequently his skeleton (231 cm [approximately 
7 ft, 7 in.] in height) was acquired by the surgeon 
John Hunter and was eventually deposited in the 
Hunterian Museum in London. In 1909, Harvey 
Cushing, a neurosurgeon from Boston, together 
with Sir Arthur Keith, the curator of the Hunterian 
Museum, examined the skeleton and opened the 
skull. They reported that the patient had an en-
larged pituitary fossa1 (Fig. 1E) and concluded 
that this case of gigantism was most likely due to 
a pituitary adenoma.19 Radiographic images of 
the wrist bones, obtained in 1980, showed that 
the epiphyses were not fused at the time of the 
patient’s death, at which point his bone age was 
estimated to be only about 17 years, according to 
current criteria.2
The family trees of the affected members of 
the four families of Northern Irish origin are 
shown in Figure 2; their case histories are pro-
vided in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.
Patients and family members gave written in-
formed consent for the study, which was ap-
proved by the relevant local ethics committees. 
The board of directors of the Hunterian Museum 
gave us permission to examine teeth from the 
18th-century index patient.
Me thods
Data on serum growth hormone levels for the 
four families were converted to current units 
(micrograms per liter) with the use of appropri-
ate conversion factors related to the growth-
Figure 1 (facing page). Images of the Index Patient 
and the Structure and Specific Mutation of AIP. 
In Panel A, the aryl hydrocarbon–interacting protein 
(AIP) sequence change c.910C→T (red arrows) generates 
a premature stop codon, resulting in a truncated protein 
with loss of the final 26 amino acids. The site appears 
to be a mutational hot spot, since it is located at a typi-
cal CpG site16 and has been identified in five families 
from three countries (three from Italy,6,16 one from 
England,10 and one from Romania10), as well as in two 
patients with apparently sporadic cases in France and 
India, in addition to the Irish cases we describe here. It 
was not found to be present in any other patients with 
sporadic or familial pituitary adenoma, in patients 
studied for AIP abnormalities who had other diseases, 
or in the general population15 (and unpublished data). 
Panel B shows schematic representations of AIP and 
the AIP protein. The red arrows point to the location  
of AIP and protein mutations. The AIP protein has 
three pairs of conserved antiparallel α helixes (tetratri-
copeptide repeat domains [TPR]) and a final extended 
α helix, α7. These helical structures are important for 
the protein–protein binding and antiproliferative action 
of AIP.10,17 Panel C shows a three-dimensional model 
of AIP based on the crystal structure of the structurally 
related protein FKBP51.13 The red amino acid is num-
ber 304, which is replaced by a termination codon in 
the families described in this study. This mutation re-
sults in a loss of 26 amino acids at the end of the α7 
helix (gray). Panel D shows the index patient beside 
the twin brothers who also had gigantism, in an etch-
ing by John Kay (1742–1826) (National Portrait Gallery, 
London). Panel E shows mi cro tomographic reconstruc-
tions of the skull of the index patient (right) alongside 
a normal male skull (left). The images have been 
clipped at the plane indicated to allow observation of 
the differences in the size of the pituitary fossa (red cir-
cles), the size of the frontal sinuses, and the thickness 
of the parietal bone (red arrow).
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hormone standards applied at the time (World 
Health Organization International Reference 
Preparations [IRP] 66/217 and 80/505). DNA from 
peripheral-blood leukocytes was extracted with 
the use of a commercial kit (Nucleon BACC 
 Genomic DNA Extraction Kit, GE Healthcare). 
DNA was extracted from the dental samples 
from the index patient in a separate laboratory 
(Mainz, Germany) with the use of previously de-
scribed methods.20 The sequencing primers were 
as follows: for leukocyte DNA, forward primer 
GTGGCATCCTCAGGTCAG and reverse primer 
GTGGAGCAGCTCAGCAGAC; for the dental 
samples, forward primer CCCAGGAGGCCCAG-
GCTGAC TTTG and reverse primer TCTGCCG-
GATCCGTGCCTCCAG. Microsatellites and corre-
sponding primers were identified on the National 
Center for Biotechnology Information Web site 
(www.ncbi.nlm.nih.gov) and the University of 
California Santa Cruz Genome Browser Web site 
(http://genome.ucsc.edu). Simple repeats were 
identified with the use of the latter Web site and 
were designed accordingly for the specific region. 
Sequencing and fragment analysis were carried 
out according to standard protocols on a DNA 
analyzer (ABI 3730, Applied Biosystems). Sequenc-
es were compared with the published template 
(accession number, NM_003977) with the use of 
the Mutation Surveyor, version 3.20 (SoftGenetics), 
and microsatellite data were analyzed with the 
use of GeneMarker, version 1.85 (SoftGenetics). 
The March 2006 assembly (NCBI36/hg18) of the 
human genome was used for localization of the 
markers (Fig. 1 in the Supplementary Appendix). 
Data from all available family members, includ-
ing several subjects from the consanguineous 
family (Family D), were used to establish phase 
and disease-associated haplotype.
To estimate the time since the common ances-
tor of the mutant AIP allele in the four families 
and in the index patient, we applied coalescent 
theory, which is a retrospective model of gene 
genealogies for a sample from a population with 
a defined demographic history.21,22 Coalescent 
simulations were performed assuming a neutral 
locus in a random-mating population of 200,000 
Prolactinoma Tested, not carrier 
Acromegaly Obligate carrier (not tested) 
Gigantism Tested carrier 
Carrier status not known Somatomammotropinoma  
Asymptomatic microadenoma
Family A Family B
Family C Family D
*
*
Figure 2. Family Trees of the Four Families.
The pedigrees have been modified to maintain confidentiality. Arrows indicate probands, and double lines consanguineous marriage.
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chromosomes. (Other assumed population sizes 
that ranged from 2000 to 2 million chromosomes 
were tested, and the results were similar.) We 
used two different data sets to calculate the 
genetic distances for our area of interest. The 
Rutgers Combined Linkage–Physical Map23 com-
bines genotype data from the Centre d’Etude du 
Polymorphisme Humain (Paris) and from deCODE 
(Reykjavik, Iceland) pedigrees, as well as sequence-
based positional information; we used the sex-
averaged genetic distance across our region. We 
also used population-based methods of estimat-
ing recombination rates from phase 2 HapMap 
data (all populations combined, http://hapmap 
.ncbi.nlm.nih.gov/downloads/recombination/latest/
rates). Taking each estimate in turn, and assum-
ing a microsatellite mutation rate of 0.001 per 
generation, we calculated that the total rate of 
recombination plus mutation at all five micro-
satellite loci and the 304 codon of AIP was 
0.0224 (Rutgers) or 0.0165 (HapMap) per genera-
tion.24 We used the method described by Don-
nelly and colleagues25 to estimate the time to the 
most recent ancestral gene copy, given the geno-
typing data. To estimate the number of carriers 
of the c.910C→T mutation living in a single gen-
eration today, we performed forward simula-
tions,26 assuming a population growth of 2% 
per generation from an ancestral population of 
10,000 (results were little affected by changes in 
these values). The assumed times to the most re-
cent ancestral gene copy were drawn from the 
distribution obtained above, and simulations were 
performed with the condition that the present 
generation includes at least four carriers. Micro-
tomographic images of the skull of the index 
patient were obtained at the Natural History 
Museum in London with the use of the HMX ST 
225 cone-beam system (X-Tek) and were virtu-
ally dissected with the use of VGStudio MAX 2.0 
(Volume Graphics).
R esult s
Two teeth were removed from the skull of the 
index patient. After the extraction of DNA, poly-
merase-chain-reaction amplification and sequenc-
ing were performed on both tooth samples for 
the region flanking the R304 site in four differ-
ent reactions. All eight products contained the 
heterozygous c.910C→T change.
To investigate whether the four families carry 
the c.910C→T mutation by common descent, we 
typed seven microsatellites distal to and seven 
proximal to AIP in subjects from the four living 
families and from the index patient (Fig. 3, and 
Fig. 1 in the Supplementary Appendix). We found 
a single common haplotype in a region between 
microsatellite markers Chr11-64-TG-110 and 
D11S987 spanning 2.68 megabases (Mb) shared 
among all five lineages. The shared haplotype 
might extend from Chr11-64-AC-110 to Chr11-
67-TG-107, covering 3.50 Mb, but to be conserva-
tive, we used the minimal shared region (2.68 Mb) 
in our calculations. We also typed these microsat-
ellites in a sporadic case of gigantism in a patient 
from India who carried the c.910C→T mutation. 
This patient did not share the common haplotype 
found in the four Irish families. Since the vali-
dated microsatellites are highly polymorphic in the 
common region (heterozygosity scores between 
0.58 and 0.82, National Center for Bio tech nology 
Information [http://ncbi.nlm.nih.gov]), the shar-
ing of the five microsatellite alleles and the 
c.910C→T mutation in AIP strongly supports the 
hypothesis of a single, shared haplotype span-
ning this genomic region and carrying the same 
founder c.910C→T mutation.
According to the Rutgers genetic map, the ge-
netic distance across the minimal region (2.68 Mb, 
including the five markers shared by the index 
patient and the four families) is 1.74 centimorgans 
(cM), whereas the population-based HapMap data 
results in a map distance of 1.15 cM. Both esti-
mates are subject to some uncertainty, and the 
true map distance probably lies between these 
estimates. Given the observation of a shared 
haplotype, the coalescent-theory estimate of the 
time since the most recent common ancestor is 
57 generations (95% credible interval, 15 to 132), 
or between 375 and 3300 years ago, assuming a 
mean intergenerational time of 25 years,27 based 
on the Rutgers genetic-map distance, and 66 
generations (95% credible interval, 17 to 150), or 
between 425 and 3750 years ago, based on the 
HapMap estimate. With the condition that the 
present generation includes at least four carriers, 
and with the use of the above distribution of val-
ues for the number of generations since the muta-
tion arose, forward simulations indicate that the 
expected number of carriers in one generation 
would be 68 (95% credible interval, 5 to 350) and 
90 (95% credible interval, 5 to 500), according to 
the two genetic-map estimates, respectively.
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Discussion
We identified a common haplotype that includes 
the c.910C→T, p.R304X AIP mutation in four fam-
ilies with familial isolated pituitary adenoma and 
in a giant from 18th-century Northern Ireland; 
this haplotype was absent in a sporadic case of 
gigantism in a patient from outside the British 
Isles who also carries this hotspot mutation. We 
suggest that these Irish patients with gigantism, 
acromegaly, and prolactinoma, including the in-
dex patient, carry the c.910C→T mutation through 
a common ancestry. Furthermore, coalescent anal-
ysis allowed us to estimate that the mutant allele 
was carried by an ancestor around 57 to 66 gen-
erations ago (1425 to 1650 years ago), although 
the 95% credible intervals for this estimate are 
wide. The number of carriers of this haplotype in 
the generations of family members who are now 
alive could be several hundred.
We describe 14 mutation-positive subjects: 
10 with growth hormone–secreting adenomas, 
2 with prolactin-secreting adenomas, 1 with mixed 
growth hormone– and prolactin-secreting adeno-
ma, and 1 with a microadenoma but no apparent 
hormonal abnormalities. Eight of these 10 sub-
jects had childhood-onset disease (7 had gigan-
tism and 1 had a macroprolactinoma), 4 had a 
history compatible with pituitary apoplexy, and 
3 were identified as a result of clinical screening 
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Figure 3. Microsatellite Data for the Index Patient, Mutation Carriers from the Four Contemporary Irish Families, and a Non-Irish Patient 
with Sporadic Gigantism.
For the four Irish families, the microsatellite data shown are for mutation carriers from the eldest available generation. The green area  
is the conserved region around the R304X mutation among the five lineages; the red bands represent the mutant c.910T allele, and the 
black bands represent the wild-type c.910C allele. Numbers next to the identification number of the microsatellite represent the length 
in base pairs of the microsatellite assay products. Data in red denote findings that differ from those in the other families. For the index 
patient, we were unable to infer the phase of alleles 95 and 101 at Chr11-64-AC-110 and of alleles 104 and 106 at D11S1883 because none 
of the other patients studied carried these alleles. The minimal common region for the index patient and the four families is 2.68 mega-
bases (Mb), which is equivalent to 1.74 centimorgans (cM) according to the Rutgers map and 1.15 cM according to the HapMap.
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of carrier subjects. Pituitary adenomas do not 
become manifest in every person who carries the 
heterozygous AIP mutation, a finding that is con-
sistent with previous observations.6-10,13 In the 
four families, we identified 51 carriers of the 
mutation but only 14 affected subjects. The level 
of penetrance, however, is difficult to establish, 
since we lack genetic and clinical data for all the 
carriers and for the subjects who are at risk for 
inheriting the mutation. Furthermore, there is 
an ascertainment bias for the presentation of 
affected subjects; thus, the true penetrance is 
probably lower than can be predicted from the 
available data.
On the basis of these studies, we believe that 
the index patient, and possibly the giant twin 
brothers from the neighboring village who lived 
contemporaneously (if indeed they were related 
to the index patient [Fig. 1D]), carried the same 
founder mutation as the four contemporary 
families of Northern Irish origin whom we have 
evaluated.
Gigantism and acromegaly have been described 
since ancient times.28 Wier provided the first ac-
curate medical description of acromegaly in the 
16th century,29 whereas the name of the disease 
and the identification of the full clinical picture 
originate from Pierre Marie.30 The link between 
a pituitary adenoma and clinical acromegaly and 
gigantism was not recognized until the second 
part of the 19th century.31-33 Acromegaly was ini-
tially considered to be an acquired disease, where-
as gigantism was considered to be a congenital 
disorder.34 With data emerging on AIP mutations 
in patients with familial acromegaly, it appears 
that this old dogma might, ultimately, have some 
truth, since we have now shown that one of the 
most famous giants in the medical literature did 
indeed harbor an inherited predisposition to the 
disease and that the mutation responsible for 
this predisposition persists in the contemporary 
population of Ireland.
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